Faculty Bios top

Dara L. Aisner, MD, PhD
Assistant Professor
Department of Pathology
Co-Director of the Colorado Molecular Correlates Laboratory
University of Colorado School of Medicine
University of Colorado Cancer Center
Denver, CO

Dara L. Aisner, MD, PhD top

Dr. Dara Aisner is a board-certified certified pathologist and is currently eligible for board certification in Molecular Genetic Pathology. She is an Assistant Professor at the University of Colorado School of Medicine in Denver, Colorado and a member of the University of Colorado Comprehensive Cancer Center. She has held this position since 2010.

She is a member of numerous oncology pathology and guidelines committees including the College of American Pathologists (CAP), Association for Molecular Pathology, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer, among many others. She is a member of the United States and Canadian Academy ies of Pathology Dr. Aisner is a leader among her academic peers in helping establish formal processes helping medical oncologists and pathologists work optimally together, which is especially important in today’s world of companion diagnostics, personalized medicine and Next-generation sequencing testing.

Dr. Aisner is the recipient of numerous awards, special recognitions and honors including:

  • CAP Foundation Research Grant, 2009-2010; Project Title: Identification and Validation of Gene Targets for CpG Promoter Methylation for Risk Stratification in GIST
  • REACH Resident Research Award Grant, 2009-2010; Project Title: MicroRNA Expression in H.pylori associated Gastric Carcinogenesis
  • H.T. Enterline Surgical Pathology Fellowship Award; University of Pennsylvania; June 2009
  • Merck Scholars Training Grant, University of Texas Southwestern Medical School Medical Scientist Training Program
  • Magna cum Laude; Vanderbilt University; June 1996
  • Phi Beta Kappa; Vanderbilt University; March 1996

Dr. Aisner’s academic education background is as follows

  • 7/2009 – 6/2010 | Fellow, Molecular and Genetic Pathology, Department of Pathology and Laboratory Medicine, University of Pennsylvania Hospital - Philadelphia, Pennsylvania
  • 7/2008 - 6/2009 | Fellow, Surgical Pathology Department of Pathology and Laboratory Medicine, University of Pennsylvania Hospital - Philadelphia, Pennsylvania
  • 7/2007 - 6/2008 | Resident/Clinical Fellow, Anatomic Pathology; National Institutes of Health, & 7/2004 - 9/2006 Bethesda, Maryland
  • 5/1996 - 6/2004 | MD; University of Texas Southwestern Medical School at Dallas - Dallas, Texas
  • 5/1996 - 6/2004 | PhD; University of Texas Southwestern Graduate School - Dallas, Texas
  • 8/1992 - 6/1996 | BS, Magna Cum Laude, Molecular Biology with honors; Vanderbilt University - Nashville, Tennessee

Dr. Aisner is the author of numerous publications and book chapters.

Joseph S. Bailes, MD
Medical Oncologist
Texas Oncology, PA (TOPA)
Frisco, TX

Joe Bailes, MD top

Dr. Joseph S. Bailes is a medical oncologist with substantial experience in legislation, public policy and advocacy, as well as the business aspects of the practice of oncology and of medicine generally. For nearly two decades, Dr. Bailes served in various leadership capacities for the American Society of Clinical Oncology (ASCO). During his ten years as Chair of ASCO's Clinical Practice Committee, he led a number of legislative and regulatory initiatives that helped to shape the current environment for regulation and reimbursement of cancer care in the United States. He also oversaw the creation of ASCO's State/Regional Affiliates Program to enhance participation of community oncologists in the activities of the national organization. He served on the ASCO Board of Directors in the mid-1990's and was elected President of ASCO in 1999-2000. Subsequent to his Presidency, Dr. Bailes remained engaged in ASCO policy development.

For several years, he served as Chair of the ASCO Government Relations Council, a position that was responsible for ASCO's involvement in legislative, regulatory and public policy matters affecting cancer clinical research and treatment. During 2005 and 2006, Dr. Bailes was also involved in the day-to-day governance of ASCO as the Society's Interim Chief Executive Officer(CEO). During his tenure as Interim CEO, his responsibilities included budget and staffing oversight for both ASCO and the ASCO Foundation. Dr. Bailes served as Chair of the ASCO Foundation from 2007-2009.

Dr. Bailes also has many years of experience in the practice of oncology in the private sector as a former partner in Texas Oncology, P.A., the largest oncology practice group in the country, and was a founding member of Physician Reliance Network (PRN), one of the corporate predecessors to US Oncology, Inc. Dr. Bailes served as President of PRN Research, where he oversaw clinical trials and drug development activities for the physician network. Subsequently, he was Executive Vice President for Clinical Affairs with US Oncology. He served on the Board of Directors of Ilex Oncology. In 2007, Dr Bailes was appointed to the Cancer Prevention and Research Institute of Texas (CPRIT) Oversight Committee by Texas House of Representatives Speaker Tom Craddick, serving until 2013.

Dr. Bailes received his medical degree from the University of Texas Southwestern Medical School at Dallas in 1981, followed by his internship and residency at Parkland Memorial Hospital in Dallas. He completed his Medical Oncology/Hematology Fellowship at the University of Texas Health Science Center in San Antonio in 1986. In 1994, the American Society of Internal Medicine named Dr. Bailes the Outstanding Young Internist of America. In addition to his private practice experience, Dr. Bailes has served as Clinical Assistant Professor at the University of Texas Health Science Center.

Ethan Basch, MD, MSc
Professor, Heath Policy and Management
Director, Cancer Outcomes Research Program
Lineberger Cancer Center
Associate Professor, Hematology and Oncology
University of North Carolina
Chapel Hill, NC

Ethan Basch, MD, MSc top

Dr. Ethan Basch is a medical oncologist and health services researcher. His clinical expertise is prostate cancer, and his research expertise includes patient-reported outcomes, drug regulatory policy, and comparative effectiveness research. He is also an Associate Editor of the Journal of the American Medical Association (JAMA).

He is a federally appointed member of the Methodology Committee of the Patient-Centered Outcomes Research Institute (PCORI), a member of the Board of Directors of the International Society for Quality of Life Research (ISOQOL), Co-Chair of the Health Outcomes Committee of the Alliance for Clinical Trials in Oncology, and a member of the Board of Scientific Advisors of the National Cancer Institute. He led the National Cancer Institute's initiative to develop a patient-reported adverse event monitoring system for use in clinical research (the “PRO-CTCAE”), and is study chair for multiple trials employing patient-reported endpoints.

Dr. Basch is the recipient of numerous awards, special recognitions and honors including:

  • Appointee, Board of Scientific Advisors
    2012, National Cancer Institute
  • Board of Directors
    2011, International Society for Quality of Life Research
  • Federal Appointee, Methodology Committee
    2011, Patient-Centered Outcomes Research Institute (PCORI)

Dr. Basch’s educational background is as follows:

  • BA, Literature, Brown University, 1989
  • MPhil, Literature, Oxford University, 1991
  • MD, Medicine, Harvard Medical School, 1998
  • MSc, Epidemiology, Harvard School of Public Health, 2005
  • Dr. Basch is the author of numerous publications and book chapters.

Paul A. Bunn, Jr., MD
Distinguished Professor
Division of Medical Oncology
University of Colorado Denver
James Dudley Chair in Lung Cancer Research
Denver, CO

Paul A. Bunn, Jr., MD top

Dr. Paul Bunn is arguably one of the most important lung cancer medical oncologist researchers today and among the few experts during the past several decades.

In 1984, Dr. Bunn was recruited to the University of Colorado Health Sciences Center as a Professor of Medicine in Medical Oncology and Head of the Division of Medical Oncology. In 1986 Dr. Bunn became the Director of the University of Colorado Comprehensive Cancer Center.

Dr. Bunn has also been President of the American Society of Clinical Oncology the leading cancer organization of oncology professionals in the world. The network of the American Society of Clinical Oncology comprises nearly 40,000 oncology professionals, about one-third being from more than 100 countries outside of the USA. This organization is dedicated to providing the highest-quality resources in education, policy, clinical research, and in advancing care for patients with cancer. The results of clinical trials presented at its annual meeting are a benchmark of year-to-year progress in the fight against cancer. ASCO’s flagship publication, the Journal of Clinical Oncology (JCO), is an authoritative resource for cancer research findings.

Dr. Bunn has also been the President and Executive Director of the International Association for the Study of Lung Cancer (IASLC) where he held both positions for almost 20 years, until 2013. Under his leadership Dr. Bunn built the IASLC to become the world’s largest association of oncologists, pathologists and healthcare professionals in lung cancer.

Dr. Bunn has also been the President of the Association of American Cancer Institutes (AACI) and has served on the prestigious FDA Oncology Drug Advisory Committee (ODAC) as its chairman.

He is the Chair or Co-Chair of numerous ongoing educational symposia and scientific, clinical and translational research meetings in lung cancer, including the Annual Targeted Therapies for Lung Cancer Meeting now in its seventeenth year held annually in Santa Monica, CA, the Annual Personalized Therapies and Best Clinical Practices for Lung Cancer now in its 9th year, held each year in October in San Francisco, and many others.

Dr. Bunn’s research interests focus on novel therapies for lung cancer. He has published more than 300 articles in peer-reviewed journals, over 122 reviews and editorials, and 90 book chapters on lung cancer. Dr. Bunn’s studies have set standards for the treatment of lung cancer, have identified issues of natural history and have identified biomarkers of prognosis and therapy selection. Dr. Bunn is the principal investigator on numerous national and local therapeutic trials and is also the principal investigator for the SPORE grant in lung cancer that is designed to conduct translational research in lung cancer.

Suzanne Dahlberg, PhD
Senior Research Scientist
Biostatistics and Computational Biology
Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA

Suzanne Dahlberg, PhD top

Suzanne Dahlberg is a Senior Research Scientist in the Department of Biostatistics and Computational Biology at Dana-Farber Cancer Institute, where she joined the faculty in 2006. She holds a doctorate in Biostatistics from Harvard University. Her primary research focuses on clinical and translational studies in lung cancer as the primary statistician for both the ECOG-ACRIN Thoracic Committee and the Thoracic Oncology Program at Dana-Farber Cancer Institute. In those roles, she leads the design, development, monitoring, analysis and reporting of these groups’ phase I-III clinical trials, as well as their corresponding correlative and laboratory studies. As part of the Acute Lymphoblastic Leukemia Consortium from 2006-2011, she served as the primary statistician for the adult ALL trials and their corresponding correlative studies. She is currently a member of the National Cancer Institute’s Thoracic Malignancy Steering Committee, the National Clinical Trials Network’s Core Correlative Sciences Committee, and the Scientific Advisory Board of the Lungevity Foundation. She is also the recipient of the 2016 ECOG-ACRIN Young Investigator Award.

Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP
Assistant Professor of Nursing
Division of Acute Care/Health Systems
Thoracic Oncology Program
Yale School of Nursing
Yale Cancer Center
New Haven, CT

Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP top

Dr. Marianne Davies is Assistant Professor of Nursing at Yale University School of Nursing.

She re-joined Yale University with multiple years of graduate teaching experience at Yale University School of Nursing, and has been involved at Yale-New Haven Hospital’s Cancer Center since 1983. In the past, Marianne Davies has worked as an advanced oncology certified nurse. She is currently an acute care nurse practitioner, advanced oncology certified nurse practitioner and clinical nurse specialist in adult health.

She began her nursing education at Russell Sage College in 1983. She continued her education in New Haven, Conn., and received both her Masters and Post Master’s Certificate at YSN. Marianne Davies then pursued a Doctorate of Nursing Practice at the MGH Institute of Health Profession in Boston, Mass.

In addition to teaching, Marianne Davies has received various awards and honors. She is the recipient of Cogswell Award, Outstanding Student Leadership and Community Involvement, Yale-New Haven Hospital Medical Staff Patient Experience Recognition, the Ruth McCorkle Oncology Advanced Practice Provider: Yale Cancer Center and Nightingale Award for Excellence in Nursing.

Marianne Davies also belongs to Sigma Theta Tau, the National Honor Society of Nursing, the Connecticut Nurse Practitioner Association, the Oncology Nursing Society and the International Association for the Study of Lung Cancer.

Dr. Davies is the author of numerous publications and book chapters involving oncology nursing and is considered among the top oncology nurses in the USA by her peers. She is actively involved in teaching, clinical research and also in cancer education for nurses and other oncology HealthCare Professionals. Dr. Davies is actively involved in numerous ongoing live and Web-based educational symposia including the annual Personalized Therapies and best Clinical Practices for Lung Cancer Symposium, now in its 9th year. She is also actively involved with annual Oncology Nursing Society and Advanced Nurse Practitioner educational activities.

Dr. Davies is the author of numerous publications and book chapters regarding oncology and cancer nursing.

John Fox, MD, MHA
Senior Medical Director
Priority Health
Grand Rapids, MI

John Fox, MD, MHA top

Dr. Fox is senior medical director of Medical Affairs for Priority Health, a provider-sponsored health plan with 727,000 members headquartered in Grand Rapids, Michigan. Dr. Fox is responsible for technology assessment, total cost of care management, and innovations. These include pay-for-value contracting, integrated specialty pharmacy management, consumer transparency, surgical optimization initiatives, and oncology medical home programs.

Prior to joining Priority Health, Dr. Fox was the chief medical officer at Physicians Plus Insurance in Madison, Wisconsin. He has also worked for the Indian Health Service and with the Epidemic Intelligence Service at the Centers for Disease Control and Prevention in Atlanta, GA

Dr. Fox has written on the use of firearms in suicides, physiatrist-led multidisciplinary spine clinics, oncology medical homes, breast cancer mortality, asthma hospitalizations, hip fractures among the elderly, medical home programs, and end-of-life care. He has also written and lectured on value-based benefit design, the impact of genomics and proteomics on future medical practice, and shared decision making in reducing unwarranted variations in surgery utilization. His current interests include the use of cost-effectiveness and number-needed-to-treat analyses in coverage determinations, specialty pharmacy management, and the effect of behavioral economics on health outcomes.

Dr. Fox received his medical degree from Johns Hopkins University School of Medicine and a master’s degree in health administration from the University of Wisconsin. He completed a pediatric internship and residency at the Johns Hopkins Hospital and a fellowship in epidemiology at the Centers for Disease Control and Prevention

Jim Koeller, MS
Professor
University of Texas at Austin
College of Pharmacy
Pharmacotherapy Division
Adjoint Professor
University of Texas Health Science Center at San Antonio
School of Medicine
Pharmacotherapy Education & Research Center
San Antonio, TX

Jim Koeller, MS top

Jim M. Koeller serves as a Clinical Professor of Medicine and Pharmacology at the University of Texas Health Science Center in San Antonio. Prior to his arrival in Texas, Professor Koeller was responsible for coordinating the Phase I Drug Development Program in the Department of Human Oncology, Wisconsin Comprehensive Cancer Center in Madison, Wisconsin.

Jim Koeller is a member of the Center for Pharmacoeconomic Studies in the College of Pharmacy at the University of Texas at Austin. He has published over 250 articles, abstracts, and book chapters with a focus on oncology practice, pharmacoeconomics, new drug development, and supportive care issues of the cancer patient. Additionally, he has given over 500 presentations related to oncology, supportive care, pharmacoeconomics, cancer disease management and health care economics.

Professor Koeller received his undergraduate and graduate degrees from the University of Wisconsin-Madison, and completed a residency at the University of Wisconsin Hospital. He holds the Eli Lilly/CR Sublett Endowed Fellowship in Pharmacy.

Professor Koeller is actively engaged in the research and publication of numerous areas of pharmacoeconomic research with oncology/hematology and supportive care cancer therapies. He is currently very actively involved with innovative models and potential new policies for improving the reimbursement of cancer healthcare by utilizing the value-based approach versus the traditional fee-for-service based system for cancer therapy payment and reimbursement.

Jim is the author of numerous cancer publications for both pharmacists and oncologists and is considered one of the best academic thought leaders in oncology/hematology economics. He is actively involved with ongoing pharmacy and oncologist education thorough various organizations including HOPA (Hematology-Oncology Pharmacy Association) as well as with other annual educational programs including the annual Personalized Therapies and Best Clinical Practices for Lung Cancer Symposium, and most recently the forthcoming 1st Annual Symposium on Integrating immune Therapy and Targeted Therapy Into Standards of Care for Hematologic and Solid Malignancies, September 10, 2016 in San Francisco.

Rogerio C. Lilenbaum, MD
Professor of Medicine
Yale School of Medicine
Chief Medical Officer
Smilow Cancer Center
West Haven, CT

Rogerio C. Lilenbaum, MD top

Dr. Rogerio Lilenbaum is a board-certified certified medical oncologist and Professor of Medical Oncology at the Yale School of Medicine and the Yale Comprehensive Cancer Center. He specializes in developmental therapeutics and thoracic oncology. Dr. Lilenbaum is also the Chief Medical Officer of the Smilow Cancer Center in West Haven, Connecticut.

Dr. Lilenbaum is a member of perhaps the world’s leading organizations for establishing treatment guidelines for using cancer therapy, the National Comprehensive Center Network (NCCN). Dr. Lilenbaum is also the Section Editor for Up-To-Date® in Lung Cancer, one of the most respected sources of lung cancer information for community and academic oncologists, particularly because it receives no funding from pharmaceutical companies and is a subscription-only product.

Dr. Lilenbaum’s academic education background is as follows

  • MS — Harvard School of Public Health, Clinical Epidemiology/Clinical Investigation (1996)
  • MD — Federal University of Rio De Janerio, Brazil (1986)
  • Fellowship — University of California - San Diego
  • Fellowship — Washington University School of Medicine
  • Residency — University Hospital Rio de Janeiro
  • Board Certification — AB of Internal Medicine, Medical Oncology (1997)
  • Board Certification — AB of Internal Medicine, Hematology (Internal Medicine) (1998)

Dr. Lilenbaum is consistently named as one of “America’s Top Physicians” and “America’s Top Oncologists.” He has authored more than 100 peer-reviewed papers and book chapters related to lung cancer.

Edward S. Kim, MD
Chair of Solid Tumor Oncology
Investigational Therapeutics
Levine Cancer Institute of the
Carolina's Heath Care System
Charlotte, NC

Edward S. Kim, MD top

Dr. Edward Kim is the Chair of Solid Tumor Oncology and Investigational Therapeutics at the Levine Cancer Institute of The Carolina’s HealthCare System.

Dr. Kim is a nationally-recognized leader in cancer research, with specialties in lung cancer, head and neck cancer and solid tumor oncology, including early drug development. Since joining the Carolina’s HealthCare System in 2012 Dr. Kim has played a key role in developing and expanding the system’s solid tumor, hematologic malignancy, biostatistics and pharmacology groups. Perhaps most notably among his various accomplishments is his expansion of the the research capacity and treatment offerings to cancer patients across the Southeastern USA. The Institute, formed in 2010 by CHS, works with affiliated hospitals and providers to facilitate innovations and enhance the quality and convenience of cancer care. Largely the result of Dr. Kim’s leadership and vast experience from his previous position at the University of Texas MD Anderson Cancer Center, he has help lead The Carolina’s HealthCare System to become one of the country’s best providers of cutting-edge cancer investigational therapies to areas that were not able to access these investigational therapies unless they went to major metropolitan areas such as New York or Boston, for treatment at either the Memorial Sloan Kettering Cancer Center or the Dana Farber Cancer Center.

Dr. Kim is recognized as a national leader in molecular prognostication for lung cancer and specializes in thoracic oncology and head and neck cancers. In his previous role as professor and oncologist at the University of Texas MD Anderson Cancer Center, he also served as that center's principal investigator for the Southwest Oncology Group (SWOG), one of the largest of the National Cancer Institute-supported cancer clinical trials cooperative groups.

Dr. Kim's clinical trial experience has strengthened the robust clinical trials program currently in place at the Levine Cancer Institute of the Carolina's Heath Care System

Named a top physician by U.S. News & World Report, Dr. Kim received his medical degree from Northwestern University through the Honors Program in Medical Education. He completed his residency at Baylor College of Medicine in Houston, Texas, and a medical oncology fellowship at the University of Texas MD Anderson Cancer Center. Dr. Kim is the author of numerous publications and book chapters.

Stephen G. Madison, BSc.Pharm, RPh, MBA, CHCP
President and CEO
Oncology Learning Center, Inc., and the
BioMedical Learning Institute
Plano, TX

Owner of InsiderMD, CPLS, Steve Madison Cancer Consulting, Oncology Insights, and Cancer Comm®
Dallas, TX

Stephen G. Madison, BSc.Pharm, RPh, MBA, CHCP top

Steve Madison has been involved with the science and business of oncology/hematology since 1983. He started his career in the field of oncology and hematology as an oncology pharmacist, employed as a pharmaceutical industry marketing executive of Bristol-Myers (BM) for the BM oncology products starting in 1983 as one of only two international marketing executives within BM. In 1983, there were only three cancer pharmaceutical companies in the USA: Bristol-Myers (BM), Mead Johnson and Adria Laboratories. Steve was fortunate to have started establishing working relationships with the academic (“KOL”) leaders in oncology and hematology at the beginning of the oncology business era, 36 years ago. And to this day in 2016, Steve has maintained his important KOL relationships beginning with his employment at Bristol-Myers, but also through his subsequent cancer education and medical advertising companies as described below.

In 1994 Steve left Bristol-Myers and founded and operated, SG Madison & Associates, a global medical/marketing communications and advertising company, which as agency of record, helped successfully launch gemcitabine, trastuzumab, rituximab, cetuximab, and several other oncology and HIV products; but primarily Steve and his medical/marketing company supported the oncology & HIV franchises of Bristol-Myers (eventually Bristol-Myers Squibb) in the US and Globally, plus the businesses of ImClone, Genentech, Lilly and several other companies not on a retainer basis.

In 1999 Steve founded the first of his two CME/CE accredited companies: the CBCE (Center for Biomedical Continuing Education) which he sold in 2001 along with his medical/marketing communications agency, SG Madison & Associates. During his tenure at his two CME/CE companies and SG Madison & Associates, Steve founded several major ongoing cancer education meetings and symposia, and at least two of which are still ongoing today, including the now 17th Annual Anti-Angiogenic Symposium held each year in La Jolla, CA, sponsored by MD Anderson Cancer Center and co-chaired by Dr. George Sledge and Lee Ellis, the now 17th Annual Targeted Therapies for Lung Cancer Meeting, held each year in Santa Monica, CA, sponsored by the IASLC co-chaired by Drs. Paul Bunn, Roy Herbst, Dave Johnson and Fred Hirsch.

In 2006 Steve founded the Oncology Learning Center, Inc., (also operated as the BioMedical Learning Institute) which conducts numerous live and Web-based oncology/hematology educational CME/CE activities, including annual satellite CME/CE symposia at the annual meetings of the American Society of Clinical Oncology, the American Society of Hematology, the San Antonio Breast Cancer Symposium, the Oncology Nursing Society and many other meetings and congresses, and including of its own, stand-alone educational events (of the BLMI) including the annual Symposium on Personalized Therapies and Best Clinical Practices for lung Cancer now in its 9th consecutive year, and its 1st Annual Symposium on Integrating Immune Therapy and Targeted Therapy into Standards of Care for Hematologic and Solid Malignancies to be held on September 10, 2016 in San Francisco.

In addition, Steve and the Oncology Learning Center have now resumed the highly successful Cancer Master Classes that were suspended in 2005, beginning with the October 19-21, 2016 Strategic Cancer Business Master Class and Other Master Classes will follow shortly. Please see: www.OncologyLearningCenter.com

Finally, Steve owns but does not (presently) operate several other cancer businesses of importance to pharmaceutical and diagnostic/laboratory companies, including his cancer consulting company, Steve Madison Cancer Consulting, as well as his oncology KOL development company: InsiderMD.com; his customized oncology training company: CPLS.com (Customized Pharmaceutical Learning Systems), and also his customized cancer market research company: Oncology Insights.com. The reason for Steve’s lack of involvement (for the present), is the 2009 legislation prohibiting his participation in both CME and non CME companies. It is anticipated that this will change in the very near future as Steve his other executives to operate his CME business, thus enabling Steve to operate freely inside his non-CME businesses: InsiderMD.com, CPLS.com (Customized Pharmaceutical Learning Systems), Steve Madison Consulting.com and Oncology Insights.com. Should anyone be interested in any of these business or their services please contact Steve.Madison@CPLS.com.

Jeffrey F. Patton, MD
Chief Executive Officer
Tennessee Oncology
Nashville, TN

Jeffrey F. Patton, MDtop

Jeffrey Patton, M.D. serves as Chief Executive Officer and Chairman of the Board for Nashville-based Tennessee Oncology, one of the largest community oncology practices in the U.S.

He is nationally recognized in the oncology community for his extensive clinical trial research and scholarly publications on advancing cancer treatment and bringing exceptional care to the communities where patients live. Dr. Patton has published eight manuscripts and nearly 20 clinical trial abstracts on cancer treatment research. He specializes in all adult malignancies and holds memberships in the Tennessee Oncology Practice Society and the American Society of Clinical Oncology, where he serves on the ASCO Clinical Practice Committee.

Dr. Patton, a graduate of Eastern Virginia Medical School in Norfolk, completed his residency and fellowship at Wake Forest University in Winston-Salem, N.C., where he served as Chief Resident. He also holds a B.A. in Psychology from the University of Virginia. He currently serves as Chairman of the Southern Oncology Board of Directors and is on the board of directors for PearlPoint Cancer Support. He previously served as Chief of Staff for Southern Hills Medical Center and on the board of directors for the Sarah Cannon Research Institute.

Dr. Patton is also co-founder and Chief Medical Officer of Raintree Oncology Services, a provider of comprehensive oral drug acquisition and management services to help community oncology practices improve and advance patient care.

Dr. Patton lives in Brentwood, Tenn. with his wife, Mary, and two children, Ashley and Evan. When he is not seeing patients, Dr. Patton enjoys golfing, reading and spending time with his family.

Blase Polite, MD
Assistant Professor of Medicine
University of Chicago Medicine
Center for Clinical Cancer Genetics and Global Health
Chicago, IL

Blase Polite, MD top

Dr. Blase Polite, has expertise in the treatment of gastrointestinal malignancies, with a particular focus on colon, rectal, and anal cancers, and neuroendocrine (carcinoid) tumors.

In conjunction with the Center for GI Oncology, Dr. Polite works closely with national and international experts in surgical and radiation oncology and interventional gastroenterology. Through this team approach, individualized treatment plans can be established for each patient.

He lectures and publishes on these topics, and serves on a national scientific advisory panel charged with selecting the top research abstracts to be presented at national meetings for GI cancers. He is also frequently asked to perform peer review of research being considered for publication in major medical journals.

Dr. Polite has initiated several clinical research trials aimed at advancing our treatment of colon and rectal cancer at all stages including for individuals whose tumor has grown despite standard treatments.

In addition to his primary clinical responsibilities, Dr. Polite’s research has focused on understanding racial and ethnic differences in colon cancer outcomes, with a focus on understanding the psychological, social, and spiritual needs of each patient.

Dr. Polite is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology, the American Society of Physicians, the American Society of Cancer Research, and the Cancer and Leukemia Group B.

He is highly published, authoring many peer reviewed publications and book chapters.

Suresh S. Ramalingam, MD
Professor of Hematology/Oncology
Deputy Director
Winship Cancer Institute
Director, Lung Cancer Program
Winship Cancer Institute
Assistant Dean for Cancer Research
Co-Leader, Discovery & Developmental Therapeutics Program
Emory University
Atlanta, GA

Suresh S. Ramalingam, MD top

Dr. Suresh Ramalingam is a key member of the Emory University and Winship Cancer Institute Oncology programs. He is a nationally-recognized leader in cancer research, with specialties in lung cancer, drug discovery and early drug development.

Dr. Ramalingam is certified by the American Board of Medicine and Internal Medicine and Medical oncology and as an active member of the American Society of Clinical Oncology, American Association for Cancer Research and the International Association for the Study of Lung Cancer.

Dr. Ramalingam serves on several international, national and Institutional Committees. He is currently a recipient of peer-reviewed grants from the National Cancer Institute.

Dr. Ramalingam received his MB/BS from Kilpauk Medical College. University of Madras, Madras, India in 1992. He completed his residency in internal medicine at Wayne State University in 1996 where he was also named chief medical resident in department of internal medicine in 1996. He completed his fellowship in hematology and medical oncology at the University of Pittsburgh Cancer Institute 2002.

Dr. Ramalingam’s research currently involves the development of agents that inhibit the mTOR, HDAC, DNA repair and EGFR pathways and in the evaluation methods to individualized therapies for patients. He has conducted several early-phase clinical trials with molecularly targeted agents in the treatment of small cell and Non-small cell lung cancers.

Dr. Ramalingam has authored over 200 scientific publications as the section editor for “Chest Diseases” for the Journal, Cancer. He is also on the editorial boards on the the Journal of Clinical Oncology, Annals of Oncology, and Clinical Lung Cancer.

Dr. Ramalingam is also the recipient of several awards including “James Eckman Award for Excellence in T,” at the Department of Hematology and Medical Oncology of Emory University, and the Distinguished Cancer Scholar Award of the Georgia Cancer Coalition. He is also a recipient of the Career Development Award of the of the American Society of Clinical Oncology (2006-2009).

Scott Ramsey, MD, PhD
Full Member,
Cancer Prevention Research Program,
Fred Hutchinson Cancer Research Center
Director,
Hutchinson Institute for Cancer Outcomes Research (HICOR)
Seattle, WA

Scott Ramsey, MD, PhD top

Dr. Ramsey is a general internist and health economist. He is a Full Member in the Cancer Prevention Program, Public Health Sciences Division at the Fred Hutchinson Cancer Research Center, where he directs Hutchinson Institute for Cancer Outcomes Research, a multidisciplinary team devoted to clinical and economic evaluations of new and existing cancer prevention, screening and treatment technologies. In addition, Dr. Ramsey is a Professor in the School of Medicine, School of Pharmacy, and the Institute for Public Health Genetics at the University of Washington.

Trained in Medicine and economics, Dr. Ramsey’s research focuses on economic evaluations in cancer. He has published widely on patterns of care, costs, and cost-effectiveness of treatments for lung, colorectal, and prostate cancer. His research portfolio and interests include: large scale SEER-Medicare/Cancer Registry data linkages, patient reported outcomes, economic modeling of health care interventions, cost-effectiveness analysis, quality of life assessment, patterns of care, health care utilization, economic burden of disease for patients and society, pragmatic trial design, early technology assessment, and stakeholder engagement.

Mary Redman, MD, PhD
Assistant Member, Cancer Prevention
Fred Hutchison Cancer Research Center
Seattle, WA
Statistician,
Southwestern Oncology Group (SWOG)

Mary Redman, MD, PhD top

Dr. Scott Ramsey is an Adjunct Professor, Health Sciences and Professor, General Internal Medicine, Fred Hutchinson Cancer Research Center.

Dr. Scott Ramsey’s research interests include health services research evaluations of genetic technologies, and also the cost effectiveness analysis as part of clinical trials. In addition, they include the population monitoring of cancer care services. He is also involved with ADVICE (Advancing Innovative Comparative Effectiveness in cancer Diagnostics) and CANCERGEN (Center for Comparative Effectiveness Research in Cancer Genomics) Dr. Scott Ramsey is also actively involved with the initiative, PHENOM (The Program in Health Economics and Outcomes Methodology.

Dr. Ramsey is the author of numerous peer-reviewed publications involving the cost and value of oncology health care. Specific publishes topics of interest include: Collaborating to boost value based care, Surviving cancer in times of financial distress, Oncologists speak out on human toll of high health care costs, cancer bankruptcy and death: study finds a link, Nation’s top oncologists take aim at sky-high drug costs, The care you want at a pivotal time in your life, Cruel choices: Buy life-saving meds or groceries? Patients take starring roles to define, shape palliate care, Easing cancers’ heavy financial burden, and numerous other publications and articles related to the cost-effectiveness and value of cancer care.

David Stewart, MD, FRCPC
Chief and Head,
Division of Medical Oncology
University of Ottawa
Ottawa Hospital
Ottawa, ON
CANADA

David Stewart, MD, FRCPC top

Dr. Davis Stewart is the Chief and Head of the Division of Medical Oncology, Ottawa Hospital and Cancer Center. He returned to the Ottawa Hospital and Cancer Center from the University of Texas MD Anderson Cancer Center in Houston, TX in August, 2011 to assume the position of Head of the Division of Medical Oncology at The Ottawa Hospital and the University of Ottawa.

Dr. Stewart received his MD degree from Queen’s University, Kingston, followed by training in Internal Medicine at McGill University and in medical oncology in the Department of Developmental Therapeutics at the UT MD Anderson Cancer Center. He first moved from the University of Texas MD Anderson Cancer Center to the University of Ottawa and the Cancer Care Ontario Ottawa Regional Cancer Center in 1980, and served as Chief of Medical Oncology at the Ottawa Civic Hospital from 1989 to 1999. He returned to the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center from 2003 to 2011 where he served as Chief of the Section of Experimental Therapeutics (2003-2005), Chair Ad Interim (2005), Deputy Chair (2006-2009), and Director of Translational Research (2009-2011). He was also the Principle Investigator of MD Anderson’ phase II N01 contract with the National Cancer Institute, and was the clinical leader of a number of other federally-funded translational research project.

Dr. Stewart’s focus clinically is therapy of advanced lung cancer. He has published more than 290 peer-reviewed papers, and edited the text Lung Cancer: Prevention, Management and Emerging Therapies published in 2010. His primary area of research interest is personalization of therapy using tools that include phase I and II clinical trials, studies of plasma pharmacokinetics and tumor and normal tissue uptake of chemotherapy agents, resistance mechanisms, resistance modulation, and host single nucleotide polymorphisms and tumor biomarkers that correlate with treatment outcome and prognosis. He has also published on the importance of raising the efficacy bar in clinical research, of fixing current regulatory problems that impede research without adding value, and of doing correlative studies starting from the earliest days of clinical development of a drug, in order to better identify patients who are most and least likely to benefit. He is strongly committed to the concept of a Molecular Medicine Laboratory at the Ottawa Hospital that enables genetic characterization of tumors, thereby permitting choice of the optimal therapy approaches for individual patients.

Guneet Walia, PhD
Sr. Director, Research and Medical Affairs
Bonnie J. Addario Lung Cancer Foundation
San Carlos, CA

Guneet Walia, PhD top

Coming soon.

H. Jack West, MD
Medical Director, Thoracic Oncology Program
Swedish Cancer Institute
President and CEO
Global Resource for Advancing Cancer Education
Seattle, WA

H. Jack West, MD top

Dr. West received an MPhil in Experimental Biology from Cambridge University on a Fulbright Scholarship and a medical degree (magna cum laude) from Harvard Medical School, where Dr. West also conducted research as a Howard Hughes Medical Student Fellow. His postdoctoral training included an internship and residency in internal medicine at the Harvard-affiliated Brigham and Women’s Hospital Boston, MA, followed by a fellowship in medical oncology at the Fred Hutchinson Cancer Research Center/ University of Washington in Seattle, WA. He joined Swedish Cancer Institute in late 2002 as a medical oncologist and lung cancer specialist. He also serves as Medical Director of the Thoracic Oncology Program and has a significant clinical interest as well in genitourinary oncology.

Dr. West has published numerous articles in peer-reviewed literature and has authored several book chapters. He also now serves as the Web Editor of JAMA Oncology and is on the editorial boards of Journal of Clinical Oncology, Journal of Medicine, Clinical Lung Cancer, and Journal of Thoracic Disease, in addition to serving as an author of multiple lung cancer-related sections of Up-To-Date and as a reviewer for more than a dozen professional journals. Dr. West leads a wide range of clinical trials and has been actively involved with the SWOG Lung Cancer Committee as a Study Coordinator/Principal Investigator.

Dr. West founded and continues to serve as President of the nonprofit organization Global Resource for Advancing Cancer Education (GRACE), a source of timely, free information for patients and caregivers dealing with cancer that currently receives over 50 thousand visits per month from over 100 countries around the world.

Dr. West is also working to develop telemedicine-based practice patterns to broaden the range of treatment options for cancer patients and serves as the Chair of the Outreach/Education/Telemedicine Working Group for the Cancer Clinical Provider Group as part of the Providence/Swedish Hospital Network. He is also a regular session chair on numerous annual lung cancer an immune and targeted therapy CME symposia such as the Annual Personalized Therapies and Best Clinical Practices Symposia each year in October in San Francisco. He is often a co-chair of satellite educational symposia on lung cancer at the annual meeting of the American Society of Clinical Oncology in Chicago in May and June.

© 2018 Oncology Learning Center, Inc.